'Tis but a scratch: a critical review of the Women's Health Initiative evidence associating menopausal hormone therapy with the risk of breast cancer
- 18 October 2023
- journal article
- review article
- Published by Wolters Kluwer Health in Menopause
- Vol. 30 (12) , 1241-1245
Abstract
Use of menopausal hormone therapy (HT) fell precipitously after 2002, largely as a result of the Women's Health Initiative's report claiming that the combination of conjugated equine estrogen (CEE) and medroxyprogesterone acetate increased breast cancer risk and did not improve quality of life. More recently, Women's Health Initiative (WHI) publications acknowledge HT as the most effective treatment for managing menopausal vasomotor symptoms and report that CEE alone reduces the risk of breast cancer by 23% while reducing breast cancer death by 40%. Their sole remaining concern is a small increase in breast cancer incidence with CEE and medroxyprogesterone acetate (1 per 1,000 women per year) but with no increased risk of breast cancer mortality. This article closely examines evidence that calls even this claim of breast cancer risk into serious question, including the WHI's reporting of nonsignificant results as if they were meaningful, a misinterpretation of its own data, and the misleading assertion that the WHI's findings have reduced the incidence of breast cancer in the United States. A generation of women has been deprived of HT largely as a result of this widely publicized misinterpretation of the data. This article attempts to rectify this misunderstanding, with the goal of helping patients and physicians make informed joint decisions about the use of HT.Keywords
This publication has 42 references indexed in Scilit:
- Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trialBMJ, 2012
- Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Table 1BMJ Sexual & Reproductive Health, 2011
- Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestinMaturitas, 2006
- Brief report: Coronary heart disease events associated with hormone therapy in younger and older womenJournal of General Internal Medicine, 2006
- Low-Fat Dietary Pattern and Risk of Invasive Breast CancerJAMA, 2006
- Meta‐analysis: effect of hormone‐replacement therapy on components of the metabolic syndrome in postmenopausal womenDiabetes, Obesity and Metabolism, 2005
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancerThe Lancet, 1997
- Treatment with Tamoxifen and Progestins for Metastatic Breast Cancer in Postmenopausal Women: A Quantitative Review of Published Randomized Clinical TrialsOncology, 1993